Biosimilar Avastin Is Launched In India
Cadila Pharmaceuticals Announces Entry
Outlining plans to launch “multiple biosimilar products this year for the Indian market,” Cadila Pharmaceutical has just rolled out a biosimilar to Avastin (bevacizumab) in its domestic market.
You may also be interested in...
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
Privately owned Indian firm, Cadila Pharmaceuticals, is set to launch Mycidac-C (heat-killed mycobacterium w), a desmocollin-3 targeting active immune therapy, for non-small cell lung cancer (NSCLC) on the domestic market.